MedTrace Logo

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

NCT01486368 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-08-04

No results posted yet for this study

Summary

This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

PF-03446962

PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Quincy Chu · Cross Cancer Institute, Edmonton, AB Canada

  • Paul Wheatley-Price · Ottawa Health Research Institute - General Division, Ottawa ON Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-26
Primary Completion
2014-04-27
Completion
2015-02-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01486368 on ClinicalTrials.gov